Abstract: This 1 paper 2 solves an enhanced adaptive dynamic programming (ADP)-based collision-free enclosing learning control for Unmanned Aerial Vehicles (UAVs) to move around a specified target ...

Across industries, pricing strategies are quietly shifting. What was once a predictable rhythm of annual increases is now giving way to continuous, incremental adjustments—and, in some cases, fully ...

The Seattle Seahawks tied the Los Angeles Rams in the fourth quarter off one of the strangest plays you'll ever see ... and yet another reminder to play through the whistle. Down 30-28 with 6:23 left ...

Want to understand how neural networks actually learn? This video breaks down forward and backward propagation in a simple, visual way—perfect for beginners and aspiring AI engineers! #NeuralNetworks ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

If you feel like you’re being nickel-and-dimed everywhere you shop – you probably are. Instacart has been using a shady AI algorithm that charges different prices to different customers on the same ...

09/05/2025 Motion to extend the time to file a response from September 15, 2025 to October 15, 2025, submitted to The Clerk. 09/11/2025 Motion to extend the time to file a response is granted and the ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...